Daré launches first product Flora Sync LF5, Q2 revenue $0.2M, positive Ovaprene data

Dare Bioscience, Inc.

2026-Q2 EPS reported -$0.41 revenue$340,001

Launched Flora Sync LF5, first directly commercialized product; revenue began in July 2026.
Q2 2026 total revenue $0.2M vs $(0.02)M YoY; cost of revenues $0.3M.
Cash and equivalents ~$12.6M; working capital deficit ~$0.2M.
Positive interim Phase 3 Ovaprene results; DSMB recommends continue without modification.
DARE to PLAY Sildenafil Cream on track for Q3 2026 dispensing and revenue; prescriptions accepted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.